Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01943812

Enrollment

287

Registered

2013-09-17

Start date

2013-12-31

Completion date

2020-04-30

Last updated

2020-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Embryo Transfer, Pregnancy Loss

Brief summary

The aim of this study is to compare two FET protocols by modifying the substituted FET cycle in order to maintain a higher ongoing positive pregnancy rate and thus reduce the early pregnancy loss. Hypothesis: adding GnRH-agonist to the substituted cycle in FET treatment reduces the early pregnancy loss.

Interventions

DRUGEstradiol and progeterone

Estradiol and progesterone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Endometrial thickness ≥ 7 mm after stimulation * 18-45 years * IVF/ICSI fertilisation * BMI \> 18,5 \<30 kg/m2 * cycle length 25-34 days

Exclusion criteria

* endometrial thickness \< 7 mm or no triple layer endometrium and/or functional follicles * Uterine abnormality * Chronic medical disease * oocyte donation cycles

Design outcomes

Primary

Measure	Time frame
Pregnancy loss rate	Primary outcome is avaible after 12th week of gestational.

Secondary

Measure	Time frame
Pregnancy rate	14 days after embryo transfer.

Other

Measure	Time frame
Luteal progesterone levels	7th week of gestation

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026